Philips, HeartFlow ink co-selling, co-dev deals

Royal Philips (NYSE:PHG) said today it inked a collaborative deal with HeartFlow to promote HeartFlow’s FFRct Analysis system along with Philips’ catheters for assessing coronary arteries in patients with suspected coronary artery disease.

HeartFlow’s FFRct fractional flow reserve software is designed to aid in the diagnosis and treatment of patients with suspected coronary artery disease, providing insight into the extent of the CAD and the impact it is having on blood flow to the heart.

The collaborative deal will initially focus on the US, looking to expand globally “in the near term,” Amsterdam-based Philips said.

“Our commitment is to transform the patient experience and identify pathways that are personalized, high quality and at a lower price point. To address the burden that CAD is placing on healthcare systems and to transform the patient experience, hospitals are focused on adopting new technology that can improve the diagnosis and care of these patients while reducing unnecessary invasive procedures. HeartFlow shares our mission of improving clinical outcomes and, through collaboration, we can advance our goal of helping healthcare providers decide, guide, treat and confirm the right therapy at the point of care,” Philips image guided therapy devices biz lead Christopher Barys said in a prepared statement.

The deal also included a co-development agreement, Philips said, which will position the companies to develop improved catheter-lab x-ray derived fractional flow reserve or instant wave-free radio solutions with the goal of improving diagnosis and treatment of CAD.

“Our collaboration agreement with Philips, which has an integrated solution within cath-labs, will help bring HeartFlow’s technology to more patients with suspected and potentially life-threatening CAD. We look forward to continuing to address unmet needs in cardiology in collaboration with Philips to further support our goal of improving patient lives and reducing the total cost of care,” HeartFlow CEO Dr. John Stevens said in a press release.

Earlier this month, Philips said it closed its $2.2 billion deal to acquire US vascular intervention device maker Spectranetics (NSDQ:SPNC).

The post Philips, HeartFlow ink co-selling, co-dev deals appeared first on MassDevice.

from MassDevice http://ift.tt/2vCUNlq